UBS sets USD 53.00 target for Nektar Therapeutics stock

Published on 10/15/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nektar's market value was USD 1.1 billion on October 15, 2026. Nektar Therapeutics stock costs EUR 33.72 on October 15, 2026 at 9:14 p.m. CEST.

Analyst view and market measures

UBS analyst Alice Nettleton assigned a USD 53.00 target to Nektar Therapeutics on October 13, 2026.
Nektar Therapeutics had a market capitalization of USD 1.1 billion on October 15, 2026.
Nektar Therapeutics stock costs EUR 33.72 at Lang & Schwarz on October 15, 2026 at 9:14 p.m. CEST, while Nasdaq was up 2.56 percent on the day.
Nektar Therapeutics reported USD 10.13 million in second-quarter 2026 revenue.

NKTR, US6402683063, Illustration mit AI erstellt.

UBS analyst Alice Nettleton assigned Nektar Therapeutics a Hold rating and a USD 53.00 price target on October 13, 2026, according to The Globe and Mail. Against the Nasdaq quote of USD 37.83 at 3:20 p.m. ET on October 15, 2026, that target stands 40.10 percent above the price. At Lang & Schwarz, Nektar Therapeutics was at EUR 33.72 on October 15, 2026 at 9:14 p.m. CEST.

UBS target meets a mixed record

The UBS view adds a more cautious note to a research group that remains broadly positive. The same report placed the consensus target at USD 132.70, while the current Nasdaq quote was USD 37.83. That spread leaves the individual USD 53.00 target below the published consensus but still above the market price.

Revenue and cash define the picture

Nektar reported USD 10.13 million in revenue for the second quarter of 2026, compared with a consensus estimate of USD 10.43 million, according to MarketBeat. Cash and cash equivalents stood at USD 39.27 million on June 30, 2026, while operating cash flow was negative USD 75.77 million in the second quarter. The figures underline why analyst targets remain highly sensitive to clinical progress and financing needs.

Price position and peer comparison

The current Nasdaq quote of USD 37.83 was 2.56 percent above the prior close at 3:20 p.m. ET on October 15, 2026. MarketBeat listed a 52-week range of USD 33.40 to USD 109.00 in its October 14, 2026 report. Trading volume for Nektar was 460,766 shares against an average of 1,112,126 shares.

Comparison with peers

Nektar Therapeutics (Nasdaq, USD): plus 2.56 percent, P/E minus 5.64, market capitalization USD 1.1 billion
Insmed (Nasdaq, USD): plus 0.99 percent, P/E minus 24.02, market capitalization USD 21.6 billion
Arvinas (Nasdaq, USD): plus 3.96 percent, P/E 44.42, market capitalization USD 457.5 million

What the analyst target means

The UBS target sits materially above the current Nasdaq price, but the company remains loss-making and its second-quarter revenue came in below consensus. For investors, the gap between clinical expectations and cash consumption is the central valuation issue.

Trading level in euros

The euro quotation was EUR 33.72 at Lang & Schwarz on October 15, 2026 at 9:14 p.m. CEST. On Nasdaq, Nektar Therapeutics was last at USD 37.83 on October 15, 2026 at 3:20 p.m. ET, up 2.56 percent against the prior close. The further course of trading is shown by the continuously updated real-time quote of Nektar Therapeutics stock.